Related references
Note: Only part of the references are listed.In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
J. Scott Overcash et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria
Cecile Emeraud et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase
James Albiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales
Frieder Fuchs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2019)
Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?
George Dimopoulos et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2019)
ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections
Rodrigo M. Burgos et al.
FUTURE MICROBIOLOGY (2019)
Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study
Sergio Garcia-Fernandez et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
High Rates of Fosfomycin Resistance in Gram-Negative Urinary Isolates from Israel
Avi Peretz et al.
MICROBIAL DRUG RESISTANCE (2019)
Once-Daily Plazomicin for Complicated Urinary Tract Infections
Florian M. E. Wagenlehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia
Pranita D. Tamma et al.
JAMA INTERNAL MEDICINE (2019)
Individual and community predictors of urinary ceftriaxone-resistant Escherichia coli isolates, Victoria, Australia
Kyra Y. L. Chua et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2019)
In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study
Andrew Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?
Kellie J. Goodlet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
Michael R. Jacobs et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions
Mariana Castanheira et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Outcomes of Fosfomycin Use in Ceftriaxone-Resistant Enterobacteriaceae Urinary Tract Infection in the Elderly
Wei Ming Quek et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstreann infections in Taiwan
Shun-Chung Hsueh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Fosfomycin: mechanisms and the increasing prevalence of resistance
Mina Aghamali et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2019)
Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia
Sofia Ny et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial
Bannakij Lojanapiwat et al.
INFECTION AND DRUG RESISTANCE (2019)
Risk factors for resistance and MDR in community urine isolates: population-level analysis using the NHS Scotland Infection Intelligence Platform
William Malcolm et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections
Samantha S. Wang et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2018)
A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis
Lynn E. Connolly et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections
F. Wagenlehner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates
Andreas Vente et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers
R. A. Wijma et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015
George G. Zhanel et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016
Helio S. Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae
Kristen L. Bunnell et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Matt Shirley
DRUGS (2018)
Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016
Sibylle H. Lob et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2018)
Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain
Maria Garcia-Castillo et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae
Se Ah Kim et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
Helene Bouxom et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets
Rodrigo E. Mendes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women A Randomized Clinical Trial
Angela Huttner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis
Soo Kyung Son et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods
K. Alexandre et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme
James A. Kartowsky et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion
Wouter van den Bijllaardt et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis
Neta Sternbach et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study
Elizabeth Crellin et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study
Elizabeth Crellin et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015
Krystyna M. Kazmierczak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis
Maroun M. Sfeir et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Risk of adverse outcomes following urinary tract infection in older people with renal impairment: Retrospective cohort study using linked health record data
Haroon Ahmed et al.
PLOS MEDICINE (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae
Wenxia Zhang et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2018)
Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of Pseudomonas aeruginosa infections
Michael Hogan et al.
INFECTION AND DRUG RESISTANCE (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
The use of oral fosfomycin-trometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic?
Tommaso Cai et al.
JOURNAL OF CHEMOTHERAPY (2018)
Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in US Hospitals from 2012 to 2015
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes
Stephanie E. Giancola et al.
CHEMOTHERAPY (2017)
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials
Myra W. Popejoy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections
Mohamad-Ali Trad et al.
JOURNAL OF CHEMOTHERAPY (2017)
An update on the management of urinary tract infections in the era of antimicrobial resistance
Mazen S. Bader et al.
POSTGRADUATE MEDICINE (2017)
In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens
Maria Lina Mezzatesta et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study
Helene Guet-Revillet et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli
Young Kyung Yoon et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15)
Michael A. Pfaller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli: A pilot study
Chitprasong Malaisri et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2017)
Assessment of MIC Increases with Meropenem-Vaborbactam and Ceftazidime-Avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections)
Olga Lomovskaya et al.
Open Forum Infectious Diseases (2017)
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Dongxu Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections
A. Dalhoff et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antimicrobial Resistance of Escherichia coli Urinary Isolates in the Veterans Affairs Health Care System
Haley J. Morrill et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Randomized controlled trial of piperacillintazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum betalactamase-producing Escherichia coli
Yu Bin Seo et al.
BMC INFECTIOUS DISEASES (2017)
Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial
Pinyo Rattanaumpawan et al.
BMC INFECTIOUS DISEASES (2017)
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in US Medical Centers, 2012 to 2014
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study
Philippa C. Matthews et al.
BMC INFECTIOUS DISEASES (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Global epidemiology of urinary tract infections
Zafer Tandogdu et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2016)
Cephalothin is not a reliable surrogate marker for oral cephalosporins in susceptibility testing of Enterobacteriaceae causing urinary tract infection
Itziar Angulo Lopez et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2016)
Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections
Michael P. Veve et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014
Nadine Shehab et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department
F. Moustafa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Escherichia coli antimicrobial susceptibility profile and cumulative antibiogram to guide empirical treatment of uncomplicated urinary tract infections in women in the province of Quebec, 2010-15
Gaelle Delisle et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
Tat Ming Ng et al.
PLOS ONE (2016)
Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials
Angela Huttner et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women
Tor J. Monsen et al.
APMIS (2014)
The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli
Sun Hee Park et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli
Arne Soraas et al.
PLOS ONE (2014)
Clinical Outcomes With Extended or Continuous Versus Short-term Intravenous Infusion of Carbapenems and Piperacillin/Tazobactam: A Systematic Review and Meta-analysis
Matthew E. Falagas et al.
CLINICAL INFECTIOUS DISEASES (2013)
Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters
Nan-Yao Lee et al.
CLINICAL INFECTIOUS DISEASES (2013)
Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
Teena Chopra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
β-Lactam/β-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
Jesus Rodriguez-Bano et al.
CLINICAL INFECTIOUS DISEASES (2012)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
Kalpana Gupta et al.
CLINICAL INFECTIOUS DISEASES (2011)
Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system
Truls E. Bjerklund Johansen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Adverse events associated with intravenous fosfomycin
Amelie Florent et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae
Indran Balakrishnan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli-Related Complicated Lower Urinary Tract Infection
S. Senol et al.
JOURNAL OF CHEMOTHERAPY (2010)
Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women
D Kavatha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
